Cargando…

A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer

BACKGROUND: Adding bevacizumab to chemotherapy for recurrent, persistent or metastatic cervical cancer significantly improved overall survival (primary endpoint), progression-free survival and overall response rate in the randomized Phase III GOG-0240 trial. However, data for bevacizumab-containing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugiyama, Toru, Mizuno, Mika, Aoki, Yoichi, Sakurai, Manabu, Nishikawa, Tadaaki, Ueda, Eisuke, Tajima, Kosei, Takeshima, Nobuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421579/ https://www.ncbi.nlm.nih.gov/pubmed/27803033 http://dx.doi.org/10.1093/jjco/hyw143

Ejemplares similares

Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma(†)
por: Nagane, Motoo, et al.
Publicado: (2012)

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
por: Rosen, Virginia M., et al.
Publicado: (2017)

Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
por: Kotaka, Saki, et al.
Publicado: (2023)

Proof-of-concept single-arm trial of bevacizumab therapy for brain arteriovenous malformation
por: Muster, Rachel, et al.
Publicado: (2021)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
por: Oliva, P, et al.
Publicado: (2012)

Nasopharyngeal carcinoma treated with bevacizumab combined with paclitaxel liposome plus cisplatin: a case report and literature review
por: He, Wan, et al.
Publicado: (2016)

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
por: De Angelis, C., et al.
Publicado: (2021)

Squamous cell carcinoma arising from a mature cystic teratoma of the ovary: Successful treatment with carboplatin, paclitaxel, and bevacizumab
por: Fukase, Mika, et al.
Publicado: (2020)

Commentary: Single-use bevacizumab: The final solution?
por: Narayanan, Raja
Publicado: (2020)

Single-shot bevacizumab for cerebral radiation injury
por: Voss, Martin, et al.
Publicado: (2021)

Successful management of cutaneous lymphangitis carcinomatosa arising from cervical cancer with paclitaxel-cisplatin and bevacizumab combination therapy: a case report and review of the literature
por: Nakamura, Fumihiro, et al.
Publicado: (2019)

Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis(†)
por: Furuse, Motomasa, et al.
Publicado: (2016)

The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis
por: Funasaka, Chikako, et al.
Publicado: (2021)

Bevacizumab for Glioblastoma—A Promising Drug or Not?
por: Nagane, Motoo, et al.
Publicado: (2013)

Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study
por: Matsuoka, Ayumu, et al.
Publicado: (2016)

Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study
por: Chu, Guanghua, et al.
Publicado: (2021)

Effect of bevacizumab against cystic components of brain tumors
por: Yamasaki, Fumiyuki, et al.
Publicado: (2019)

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
por: Niyazi, Maximilian, et al.
Publicado: (2015)

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
por: Sakata, Shinya, et al.
Publicado: (2015)

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
por: Sen, Shiraj, et al.
Publicado: (2018)

A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients
por: Coltelli, Luigi, et al.
Publicado: (2022)

Atypical Choroid Plexus Papilloma Treated With Single Agent Bevacizumab
por: Kamar, Francois G., et al.
Publicado: (2014)

Tumor cell response to bevacizumab single agent therapy in vitro
por: Hein, Melanie, et al.
Publicado: (2013)

Bevacizumab as Single Agent in Children and Teenagers with Optic Pathway Glioma
por: Calò, Pierluigi, et al.
Publicado: (2023)

Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies
por: He, Liyun, et al.
Publicado: (2019)

Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report
por: Ishizuna, Kazuo, et al.
Publicado: (2013)

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
por: Tsutani, Yasuhiro, et al.
Publicado: (2018)

A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer
por: Sahai, Vaibhav, et al.
Publicado: (2019)

Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study
por: Murono, Koji, et al.
Publicado: (2023)

Combination therapy involving radiofrequency ablation and targeted chemotherapy with bevacizumab plus paclitaxel and cisplatin in a rabbit VX2 lung tumor model
por: Ueki, Ai, et al.
Publicado: (2018)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Intravitreal bevacizumab
por: Khamar, Bakulesh M
Publicado: (2018)

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
por: Shin, Donghoon, et al.
Publicado: (2020)

Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis
por: Gao, Xiaoqiang, et al.
Publicado: (2023)

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
por: Kasai, Takashi, et al.
Publicado: (2023)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qqhc5dltqu9p5ja7qcd7l12m5p